Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma (SCIN)
Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial
Sponsor: Maastricht University Medical Center
This PHASE3 trial investigates Nodular Basal Cell Carcinoma and is currently ongoing. Maastricht University Medical Center leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maastricht University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .